
Aug 19, 2025, 06:47
New Hope for Patients with BRAF V600E–Mutant Metastatic Colorectal Cancer – Fight Colorectal Cancer
Fight Colorectal Cancer shared a post on LinkedIn:
“More time. Better outcomes.
The BREAKWATER trial offers new hope for patients with BRAF V600E–mutant metastatic colorectal cancer. Researchers found that the combination of encorafenib + cetuximab + mFOLFOX6 led to improved results—and may become a new first-line treatment option.
This is personalized care in action.
If you’re living with metastatic CRC, ask your doctor about biomarker testing. Knowing your biomarkers can help guide your treatment plan.
Swipe to learn about more promising research.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 19, 2025, 06:38
Aug 19, 2025, 06:01
Aug 19, 2025, 02:37
Aug 18, 2025, 20:36
Aug 18, 2025, 20:22